133 related articles for article (PubMed ID: 12907001)
1. Predictive cancer genomics--what do we need?
Brenton JD; Caldas C
Lancet; 2003 Aug; 362(9381):340-1. PubMed ID: 12907001
[No Abstract] [Full Text] [Related]
2. The role of taxanes as a component of neoadjuvant chemotherapy for breast cancer.
Gogas H; Fountzilas G
Ann Oncol; 2003 May; 14(5):667-74. PubMed ID: 12702519
[No Abstract] [Full Text] [Related]
3. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer.
Chang JC; Wooten EC; Tsimelzon A; Hilsenbeck SG; Gutierrez MC; Elledge R; Mohsin S; Osborne CK; Chamness GC; Allred DC; O'Connell P
Lancet; 2003 Aug; 362(9381):362-9. PubMed ID: 12907009
[TBL] [Abstract][Full Text] [Related]
4. Introduction: taxoids and the management of breast cancer.
Hortobagyi GN
Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-1-S13-2. PubMed ID: 9335510
[No Abstract] [Full Text] [Related]
5. Taxotere shows significant antitumor activity in anthracycline-resistant breast cancer patients.
Oncology (Williston Park); 1994 Sep; 8(9):112. PubMed ID: 7993720
[No Abstract] [Full Text] [Related]
6. [Intra-arterial infusion chemotherapy with docetaxel for locally advanced breast cancer and inflammatory breast cancer].
Doi K; Ohchi T; Kudo S; Takahashi M; Sakamoto T; Ochiai T; Sakae T; Ishihara A
Gan To Kagaku Ryoho; 2000 Oct; 27(12):1823-5. PubMed ID: 11086421
[TBL] [Abstract][Full Text] [Related]
7. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Goble S; Bear HD
Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
[TBL] [Abstract][Full Text] [Related]
8. [A case report: effective trans-arterial neoadjuvant chemotherapy with docetaxel for a local advanced breast cancer patient].
Sakita I; Tamaki Y; Miyazaki M; Kadota M; Masuda N; Ooka M; Ohue M; Sekimoto M; Tomita N; Monden M
Gan To Kagaku Ryoho; 1999 Oct; 26(12):1955-8. PubMed ID: 10560435
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel and docetaxel. Innovation, but at what cost?
Lønning PE
Pharmacoeconomics; 1995 Jul; 8(1):1-4. PubMed ID: 10155597
[No Abstract] [Full Text] [Related]
10. Docetaxel: current status and future prospects.
Eisenhauer E
J Clin Oncol; 1995 Dec; 13(12):2865-8. PubMed ID: 8523048
[No Abstract] [Full Text] [Related]
11. The role of taxanes in the management of breast cancer.
Nabholtz JM
Semin Oncol; 1999 Jun; 26(3 Suppl 8):1-3. PubMed ID: 10403466
[No Abstract] [Full Text] [Related]
12. Docetaxel (Taxotere) for advanced breast cancer.
Med Lett Drugs Ther; 1996 Sep; 38(984):87-8. PubMed ID: 8828520
[No Abstract] [Full Text] [Related]
13. Conclusion: the place of docetaxel (Taxotere) in future therapy.
Khayat D
Anticancer Drugs; 1996 Aug; 7 Suppl 2():53. PubMed ID: 8862713
[No Abstract] [Full Text] [Related]
14. [From conquering metastatic disease to adjuvant therapy: clinical evolution of docetaxel in breast cancer].
Cartenì G
Tumori; 2001; 87(6):A1-5. PubMed ID: 11995695
[No Abstract] [Full Text] [Related]
15. [A case of docetaxel-resistant breast cancer responsive to paclitaxel therapy].
Oura S; Tanino H; Yoshimasu T; Sakurai T; Nakamura T; Kokawa Y; Matsuyama K; Naito Y
Gan To Kagaku Ryoho; 2001 Apr; 28(4):511-4. PubMed ID: 11329786
[TBL] [Abstract][Full Text] [Related]
16. An expanding role for docetaxel.
Hortobagyi G
Semin Oncol; 1998 Dec; 25(6 Suppl 13):1-3. PubMed ID: 9865684
[No Abstract] [Full Text] [Related]
17. Use of taxanes in the treatment of patients with breast cancer has increased dramatically over the past 8 years.
Partridge A; Winer E
Clin Breast Cancer; 2000 Jul; 1(2):164-5. PubMed ID: 11899655
[No Abstract] [Full Text] [Related]
18. Cost utility in second-line metastatic breast cancer.
Berdeaux G; Hurteloup P
Pharmacoeconomics; 1997 May; 11(5):492-7. PubMed ID: 10168037
[No Abstract] [Full Text] [Related]
19. [Taxenes: a new hope of clinical oncology in the 90-ies].
Shparik IV
Vopr Onkol; 1995; 41(1):7-12. PubMed ID: 7667946
[No Abstract] [Full Text] [Related]
20. [Taxotere: the first drug better than acrdiamycin, the most frequently used drug in the treatment of metastasized breast cancer. Phase III study shows a better response than standard treatment].
Oncologica; 1997 Aug; 14(3):23-4. PubMed ID: 9481342
[No Abstract] [Full Text] [Related]
[Next] [New Search]
